Related Experiment Videos
BCL-2 and P53 expression in endometrial carcinoma
1Dept. of Obstetrics and Gynecology, Baskent University School of Medicine, Adana, Turkey. serkanli@turk.net
Summary
Bcl-2 expression decreases in endometrial carcinoma and is not linked to prognostic factors or p53. Abnormal p53 protein is crucial in aggressive serous tumors, unlike endometrioid tumors.
Area of Science:
- Oncology
- Molecular Pathology
- Gynecologic Pathology
Background:
- Bcl-2 and p53 protein expression are investigated in endometrial carcinoma.
- Understanding their roles aids in differentiating tumor subtypes and predicting prognosis.
Purpose of the Study:
- To compare bcl-2 expression with clinicopathological prognostic factors in endometrial carcinoma.
- To compare p53 expression with different endometrial carcinoma subtypes.
- To investigate the relationship between bcl-2 and p53 expression.
Main Methods:
- Immunohistochemical staining of formalin-fixed, paraffin-embedded tissue sections.
- Utilized specific antibodies for bcl-2 and p53 immunostaining.
- Analyzed expression in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma.
Main Results:
- Bcl-2 protein was expressed in 21/35 (60%) of endometrial carcinomas.
- Bcl-2 expression showed no correlation with age, surgical stage, or histopathological features.
- p53 expression was significantly higher in serous papillary carcinoma (3/4 cases) compared to endometrioid carcinoma (5/31 cases).
Conclusions:
- Bcl-2 expression decreases in endometrial carcinomas, with mechanisms beyond p53 potentially regulating its expression.
- Abnormal p53 protein expression is a key event in serous tumor development, contributing to their aggressiveness.
- p53 plays a less significant role in endometrioid endometrial carcinoma development.